Biomarkers for cognitive impairment and dementia in elderly people

[1]  Wiesje M. van der Flier,et al.  CSF biomarker levels in early and late onset Alzheimer's disease , 2009, Neurobiology of Aging.

[2]  K. Blennow,et al.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease , 2009, Neurobiology of Aging.

[3]  P. Calabresi,et al.  Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies , 2008, Biological Psychiatry.

[4]  R. Katzman.,et al.  The Prevalence and Malignancy of Alzheimer Disease A Major Killer , 2008, Alzheimer's & Dementia.

[5]  F. Jessen,et al.  Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study , 2008, Neurobiology of Aging.

[6]  Hae Ri Na,et al.  Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: Candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease , 2008, Neuroscience Letters.

[7]  J. Becker,et al.  Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.

[8]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[9]  K. Blennow,et al.  Prediction of Alzheimer’s Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides , 2008, Neurodegenerative Diseases.

[10]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[11]  B. Hyman,et al.  Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.

[12]  S. Papageorgiou,et al.  Diagnostic Value of CSF Biomarker Profile in Frontotemporal Lobar Degeneration , 2008, Alzheimer disease and associated disorders.

[13]  K. Blennow,et al.  Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI , 2007, Neurology.

[14]  C. Patterson,et al.  Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging , 2007, Neurobiology of Aging.

[15]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[16]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[17]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[18]  G. Waldemar,et al.  A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia , 2007, Dementia and Geriatric Cognitive Disorders.

[19]  J. Growdon,et al.  Plasma F2A Isoprostane Levels in Alzheimer’s and Parkinson’s Disease , 2007, Neurodegenerative Diseases.

[20]  Johannes Kornhuber,et al.  Blood‐based neurochemical diagnosis of vascular dementia: a pilot study , 2007, Journal of neurochemistry.

[21]  S. Haneuse,et al.  Pathological correlates of dementia in a longitudinal, population‐based sample of aging , 2007, Annals of neurology.

[22]  C. Rowe,et al.  In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.

[23]  W. M. van der Flier,et al.  Longitudinal changes of CSF biomarkers in memory clinic patients , 2007, Neurology.

[24]  D. Perani,et al.  Reply from the authors [4] , 2007 .

[25]  Christine Van Broeckhoven,et al.  No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease , 2007 .

[26]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.

[27]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[28]  B L Miller,et al.  Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease , 2007, Neurology.

[29]  Jean-Christophe Rochet,et al.  Novel therapeutic strategies for the treatment of protein-misfolding diseases , 2007, Expert Reviews in Molecular Medicine.

[30]  D. Kiel,et al.  Inflammatory markers and the risk of Alzheimer disease , 2007, Neurology.

[31]  J. Trojanowski,et al.  TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease , 2007, Acta Neuropathologica.

[32]  A. Fagan,et al.  Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation , 2007, Annals of neurology.

[33]  B. Miller,et al.  11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.

[34]  Hilkka Soininen,et al.  CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI , 2007, Neurobiology of Aging.

[35]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[36]  R. Freedland,et al.  Increased amyloid β protein levels in children and adolescents with Down syndrome , 2007, Journal of the Neurological Sciences.

[37]  D J Brooks,et al.  DLB and PDD boundary issues , 2007, Neurology.

[38]  Keith A. Johnson,et al.  Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.

[39]  W. Jagust,et al.  Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. , 2007, Brain : a journal of neurology.

[40]  G. Davı̀,et al.  Determinants of platelet activation in Alzheimer's disease , 2007, Neurobiology of Aging.

[41]  Gunhild Waldemar,et al.  Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. , 2007, Archives of neurology.

[42]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[43]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[44]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[45]  P. Scheltens,et al.  CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls , 2007, Dementia and Geriatric Cognitive Disorders.

[46]  Norman Relkin,et al.  Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.

[47]  K. Blennow,et al.  Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.

[48]  R. Petersen.  The current status of mild cognitive impairment—what do we tell our patients? , 2007, Nature Clinical Practice Neurology.

[49]  Chris Zarow,et al.  Cognitive impact of subcortical vascular and Alzheimer's disease pathology , 2006, Annals of neurology.

[50]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[51]  O. Selnes,et al.  Vascular cognitive impairment , 2006, Nature Clinical Practice Neurology.

[52]  S. Black,et al.  National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards , 2006, Stroke.

[53]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[54]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[55]  Ge Li,et al.  Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.

[56]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[57]  Jennifer Farmer,et al.  Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.

[58]  P. Lewczuk,et al.  CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia , 2006, Brain : a journal of neurology.

[59]  T. Beach,et al.  Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects , 2006, Neurological research.

[60]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[61]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[63]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[64]  R. Maccioni,et al.  Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects , 2006, Neurobiology of Aging.

[65]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[66]  K. Blennow,et al.  Increased levels of CSF phosphorylated tau in apolipoprotein E ɛ4 carriers with mild cognitive impairment , 2005, Neuroscience Letters.

[67]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[68]  Albert Hofman,et al.  Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia , 2005, Stroke.

[69]  James P. Malone,et al.  Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S , 2005, Molecular & Cellular Proteomics.

[70]  Henrik Zetterberg,et al.  Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF , 2005, Experimental Neurology.

[71]  J. Morrow,et al.  Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.

[72]  G. Bernardi,et al.  AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis , 2005, Journal of the Neurological Sciences.

[73]  J. Kaye,et al.  Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.

[74]  J. Sidtis,et al.  Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[75]  K. Blennow,et al.  CSF biomarkers for mild cognitive impairment and early Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.

[76]  J. Schneider,et al.  Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.

[77]  M. Michalopoulou,et al.  Serum Levels of Soluble Intercellular Adhesion Molecule-1 and Soluble Endothelial Leukocyte Adhesion Molecule-1 in Alzheimer’s Disease , 2004, Journal of geriatric psychiatry and neurology.

[78]  J. Orgogozo,et al.  Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia , 2004, Journal of the Neurological Sciences.

[79]  Holly Soares,et al.  Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele , 2004, Biological Psychiatry.

[80]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[81]  J. Adair,et al.  Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease , 2004, Stroke.

[82]  H. Arai,et al.  Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. , 2004, Archives of neurology.

[83]  Peter P. Zandi,et al.  Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study , 2004 .

[84]  J. Schneider,et al.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology , 2004, Neurology.

[85]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[86]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[87]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[88]  K. Blennow,et al.  Inflammatory Markers in Matched Plasma and Cerebrospinal Fluid from Patients with Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[89]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[90]  Kaj Blennow,et al.  Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment , 2003 .

[91]  W. Markesbery,et al.  Cerebrovascular Pathology and Dementia in Autopsied Honolulu‐Asia Aging Study Participants , 2002, Annals of the New York Academy of Sciences.

[92]  H. Arai,et al.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.

[93]  Katharina Buerger,et al.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.

[94]  J. Trojanowski,et al.  Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.

[95]  K. Blennow,et al.  Neurofilament protein in cerebrospinal fluid: A marker of white matter changes , 2001, Journal of neuroscience research.

[96]  M. Sjögren,et al.  Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia , 2001, Mechanisms of Ageing and Development.

[97]  D. Schaid,et al.  Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees , 2001 .

[98]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[99]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[100]  J. Trojanowski,et al.  Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity , 2000, Annals of neurology.

[101]  Nobuyuki Okamura,et al.  CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study , 2000, Experimental Neurology.

[102]  K. Blennow,et al.  CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy , 2000, Journal of neurology, neurosurgery, and psychiatry.

[103]  C. Brayne,et al.  Neuropathological Findings in the Very Old: Results from the First 101 Brains of a Population‐based Longitudinal Study of Dementing Disorders , 2000, Annals of the New York Academy of Sciences.

[104]  G. Annoni,et al.  Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.

[105]  T. Montine,et al.  Elevated CSF prostaglandin E2 levels in patients with probable AD. , 1999, Neurology.

[106]  K. Blennow,et al.  Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment , 1999, Neuroscience Letters.

[107]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[108]  F. Schmitt,et al.  Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.

[109]  T. Montine,et al.  Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease , 1999, Neurology.

[110]  T. Montine,et al.  Increased CSF F2-isoprostane concentration in probable AD , 1999, Neurology.

[111]  J. Trojanowski,et al.  Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[112]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[113]  K. Blennow,et al.  A population study on blood-brain barrier function in 85-year-olds , 1998, Neurology.

[114]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[115]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[116]  J. Hardy,et al.  The presenilins and Alzheimer's disease. , 1997, Human molecular genetics.

[117]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[118]  H. Wiśniewski,et al.  α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease , 1994, Neurobiology of Aging.

[119]  K. Blennow,et al.  Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia , 1992, Acta neurologica Scandinavica.

[120]  S. Hirai,et al.  α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia , 1990 .

[121]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[122]  H. Engler,et al.  In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[123]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[124]  K. Blennow,et al.  Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.

[125]  G. Schellenberg,et al.  Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. , 2006, Journal of Alzheimer's disease : JAD.

[126]  T. Montine,et al.  F2-isoprostanes in Alzheimer and other neurodegenerative diseases. , 2005, Antioxidants & redox signaling.

[127]  T. Montine,et al.  Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[128]  K. Blennow.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[129]  Katharina Buerger,et al.  Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. , 2004, Archives of general psychiatry.

[130]  T. Montine,et al.  Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. , 2001, The American journal of pathology.

[131]  T. Montine,et al.  Cerebrospinal Fluid Aβ42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls , 2001 .